Javascript must be enabled to continue!
Mutation spectrum analysis of DMD gene in Indonesian Duchenne and Becker muscular dystrophy patients
View through CrossRef
Background: Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are allelic disorders caused by mutations in the DMD gene. The full mutation spectrum of the DMD gene in Indonesian patients is currently unknown. Mutation-specific therapies are currently being developed, such as exon skipping or stop codon read-through therapy. This study was conducted with the aim of identifying the mutation spectrum of the DMD gene in Indonesia to guide future development and application of feasible therapeutic strategies. Methods: This study is a cross sectional study that enrolled 43 male patients with a clinical suspicion of DMD or BMD. Multiplex ligation-dependent probe amplification (MLPA) reaction was performed to screen for the common mutations in the DMD gene. Results: Out of 43 subjects, deletions accounted for 69.77% (n=30) cases, while duplications were found in 11.63% (n=5) cases. One novel duplication spanning exons 2 to 62 was identified. Deletion mutations clustered around the distal (66.67%) and proximal (26.67%) hot spot regions of the DMD gene while duplication mutations were observed solely at the proximal region. Two false positive cases of single exon deletion detected through MLPA were attributed to sequence mutations affecting primer ligation sites, confirming the need to validate all single exon deletions when using this screening method. Analysis of available maternal DNA samples showed that the rate of de novo mutations (48.15%) appears higher than expected in this population. Out of 31 patients who were classified as DMD based on clinical and genotype characterizations, 60.47% (n=26) of cases were suitable for exon skipping therapy. Conclusion: This is the first comprehensive study showing the feasibility of implementing the MLPA method for routine screening of DMD patients in Indonesia. This is also the first study showing the potential applicability of exon skipping therapy in the majority of DMD cases in the country.
Title: Mutation spectrum analysis of DMD gene in Indonesian Duchenne and Becker muscular dystrophy patients
Description:
Background: Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are allelic disorders caused by mutations in the DMD gene.
The full mutation spectrum of the DMD gene in Indonesian patients is currently unknown.
Mutation-specific therapies are currently being developed, such as exon skipping or stop codon read-through therapy.
This study was conducted with the aim of identifying the mutation spectrum of the DMD gene in Indonesia to guide future development and application of feasible therapeutic strategies.
Methods: This study is a cross sectional study that enrolled 43 male patients with a clinical suspicion of DMD or BMD.
Multiplex ligation-dependent probe amplification (MLPA) reaction was performed to screen for the common mutations in the DMD gene.
Results: Out of 43 subjects, deletions accounted for 69.
77% (n=30) cases, while duplications were found in 11.
63% (n=5) cases.
One novel duplication spanning exons 2 to 62 was identified.
Deletion mutations clustered around the distal (66.
67%) and proximal (26.
67%) hot spot regions of the DMD gene while duplication mutations were observed solely at the proximal region.
Two false positive cases of single exon deletion detected through MLPA were attributed to sequence mutations affecting primer ligation sites, confirming the need to validate all single exon deletions when using this screening method.
Analysis of available maternal DNA samples showed that the rate of de novo mutations (48.
15%) appears higher than expected in this population.
Out of 31 patients who were classified as DMD based on clinical and genotype characterizations, 60.
47% (n=26) of cases were suitable for exon skipping therapy.
Conclusion: This is the first comprehensive study showing the feasibility of implementing the MLPA method for routine screening of DMD patients in Indonesia.
This is also the first study showing the potential applicability of exon skipping therapy in the majority of DMD cases in the country.
Related Results
Challenges in developing gene therapy against Duchenne muscular dystrophy
Challenges in developing gene therapy against Duchenne muscular dystrophy
Duchenne muscular dystrophy is a progressive X-linked recessive neuromuscular disorder resulting from pathogenic mutations in the DMD gene, which codes dystrophin. It is one of the...
Duchenne Muscular Dystrophy: Clinical Characteristics, Molecular Mechanisms and Management
Duchenne Muscular Dystrophy: Clinical Characteristics, Molecular Mechanisms and Management
The dystrophinopathies encompass a range of X-linked muscle disorders varying from mild to severe, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and...
Mutation spectrum analysis of DMD gene in Indonesian Duchenne and Becker muscular dystrophy patients
Mutation spectrum analysis of DMD gene in Indonesian Duchenne and Becker muscular dystrophy patients
Background: Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are allelic disorders caused by mutations in the DMD gene. The full mutation spectrum of the DMD g...
Duchenne muscular dystrophy (DMD) cardiomyocyte-secreted exosomes promote the pathogenesis of DMD-associated cardiomyopathy
Duchenne muscular dystrophy (DMD) cardiomyocyte-secreted exosomes promote the pathogenesis of DMD-associated cardiomyopathy
ABSTRACT
Cardiomyopathy is a leading cause of early mortality in Duchenne muscular dystrophy (DMD). There is a need to gain a better understanding of the molecular p...
Novel pathological mechanisms support new therapeutic opportunities in Duchenne Muscular Dystrophy
Novel pathological mechanisms support new therapeutic opportunities in Duchenne Muscular Dystrophy
Découverte de nouveaux mécanismes pathologiques soutenant de nouvelles opportunités thérapeutiques dans la dystrophie musculaire de Duchenne
La dystrophie musculair...
Serum titin/creatinine ratio as a biomarker for discriminating disease severity in Duchenne and Becker muscular dystrophies
Serum titin/creatinine ratio as a biomarker for discriminating disease severity in Duchenne and Becker muscular dystrophies
IntroductionDuchenne/Becker muscular dystrophies (DMD/BMD) are inherited muscle diseases, collectively referred to as dystrophinopathy, which are characterized by progressive degen...
Titin fragment is a sensitive biomarker in Duchenne muscular dystrophy model mice carrying full-length human dystrophin gene on human artificial chromosome
Titin fragment is a sensitive biomarker in Duchenne muscular dystrophy model mice carrying full-length human dystrophin gene on human artificial chromosome
Abstract
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations of the dystrophin gene, which spans 2.4 Mb on the X chromosome. Creatine ...
Duchenne muscular dystrophy gene therapy in the canine model
Duchenne muscular dystrophy gene therapy in the canine model
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] Duchenne muscular dystrophy (DMD) is a devastating muscle wasting disease caused by loss of function mutation...

